Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pharmathen s.a. - ibandronic acid - hypercalcemia; fractures, bone; neoplasm metastasis; breast neoplasms - drogi għat-trattament ta 'mard tal-għadam - concentrate for solution for infusion prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. trattament ta ' l-iperkalċemja kkawżata minn tumuri bi jew mingħajr metastażi. film-coated tablets prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - imipenem monohydrate, cilastatin tas-sodju, relebactam monohydrate - gram-negattivi infezzjonijiet tal-batterji - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 u 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4, u 5. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - sera immuni u immunoglobulini, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. ara t-taqsimiet 4. 4 u 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - doripenem - pneumonia, ventilator-associated; pneumonia, bacterial; urinary tract infections; bacterial infections; cross infection - antibatteriċi għal użu sistemiku, - doribax huwa indikat għall-kura ta 'l-infezzjonijiet li ġejjin fl-adulti:pnewmonja nożokomjali (inkluż pulmonite assoċjata ma'); infezzjonijiet intra-addominali;ikkumplikati tal-passaġġ urinarju. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

theravance biopharma ireland umited - telavancin - pneumonia, bacterial; cross infection - antibatteriċi għal użu sistemiku, - vibativ huwa indikat għat-trattament ta ' l-adulti bl-pnewmonja nosokomjali inklużi ventilaturi assoċjati pnewmonja, magħrufa jew issuspettat li jkun ikkawżat mill-awrei-reżistenti staphylococcus aureus (mrsa). vibativ għandu jintuża biss f'sitwazzjonijiet fejn huwa magħruf jew hemm suspett li l-alternattivi oħra mhumiex adattati. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eli lilly nederland b.v. - drotrecogin alfa (attivat) - sepsis; multiple organ failure - aġenti antitrombotiċi - xigris huwa indikat għat-trattament ta 'pazjenti adulti li għandhom sepsis severi b'fattil ta' organu multiplu meta miżjud ma 'l-aħjar kura standard. l-użu ta 'xigris għandu jiġi kkunsidrat prinċipalment f'sitwazzjonijiet fejn it-terapija tista' tinbeda fi żmien 24 siegħa wara l-bidu ta 'falliment ta' organi (għal aktar informazzjoni ara t-taqsima 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - tigecycline - bacterial infections; skin diseases, bacterial; soft tissue infections - antibatteriċi għal użu sistemiku, - tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: , complicated skin and soft tissue infections (cssti), excluding diabetic foot infections, complicated intra-abdominal infections (ciai) , tygacil should be used only in situations where other alternative antibiotics are not suitable. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi. l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibatteriċi għal użu sistemiku, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - antibatteriċi għal użu sistemiku, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - memantina idrokloridu - marda ta 'alzheimer - other anti-dementia drugs, psychoanaleptics, - trattament ta 'pazjenti b'mard ta' alzheimer moderat għal sever.